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Severe myoclonic epilepsy of infancy (SMEI) is a rare disorder that occurs in isolated patients. The disease is
characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin
during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, andsimple
and complex partial seizures. Psychomotor development stagnates around the second year of life.Missensemutations
in the gene that codes for a neuronal voltage-gated sodium-channel a-subunit (SCN1A) were identified in families
with generalized epilepsy with febrile seizures plus (GEFS+). GEFS+ is a mild type of epilepsy associated with febrile
and afebrile seizures. Because both GEFS+ and SMEI involve fever-associated seizures, we screened seven unrelated
patients with SMEI for mutations in SCN1A. We identified a mutation in each patient: four had frameshiftmutations,
one had a nonsense mutation, one had a splice-donor mutation, and one had a missense mutation. All mutations
are de novo mutations and were not observed in 184 control chromosomes.
Introduction
Severe myoclonic epilepsy of infancy (SMEI) was first
described by Dravet in 1978 and is included as an ep-
ileptic syndrome in the International League Against Ep-
ilepsy (ILAE) classification, which was proposed by the
Commission on Classification and Terminology of the
ILAE (1989). Early manifestations of the disease are
tonic, clonic, and tonic-clonic seizures that occur within
the first year of life. These seizures are often prolonged,
generalized, and associated with fever. Later in life, pa-
tients with SMEI have afebrile seizures, including my-
oclonic, tonic-clonic, absence, and simple and complex
partial seizures. Early psychomotor and speech devel-
opment is normal, but developmental stagnation occurs
during the second year of life. Patients often become
ataxic, and speech development is delayed. In general,
SMEI is very resistant to all forms of pharmacotherapy.
A mild phenotype characterized by febrile seizures
and, occasionally, epilepsy in adulthood was de-
scribed by Scheffer and Berkovic (1997) as “gener-
alized epilepsy with febrile seizures plus” (GEFS)
(MIM 604233). Two families with GEFS were re-
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ported to segregate missense mutations in the gene that
codes for the a-subunit of a neuronal voltage-gated so-
dium channel (SCN1A) located on chromosome 2q (Es-
cayg et al. 2000). Both mutations are within the trans-
membrane segments DII S4 and DIV S4 (fig. 1), which
are voltage sensors of the channel. Recently, additional
families with GEFS were reported to have novel mis-
sense mutations in SCN1A (Escayg et al. 2001; Wallace
et al. 2001), which were located in the linker between
DII and DIII and in the DI S2-S3 loop, DIII S5, and
DIV S4 (fig. 1).
Because fever-induced seizures occur both in GEFS
and SMEI, we screened SCN1A for mutations in seven
patients with SMEI.
Subjects and Methods
Subjects
We studied seven Belgian patients with SMEI, diag-
nosed according to the criteria of the Commission on
Classification and Terminology of the ILAE (1989).
DNA was extracted from peripheral blood of the seven
patients, their unaffected parents, and 92 healthy control
persons randomly selected from the Belgian population.
The study was approved by the Commission forMedical
Ethics of the University of Antwerp.
Human SCN1A
We defined the exon-intron boundaries of SCN1A by
aligning the genomic sequence contained in BAC clone
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Figure 1 Organization of SCN1A. The neuronal voltage-gated sodium-channel a-subunit SCN1A is a monomer and consists of four
homologous domains (DI–DIV). Each domain has six transmembrane segments (S1–S6). S4 has several positively charged amino acids and
represents the voltage sensor. Pp the pore loop, which delineates the pore of the channel. Mutations identified in this study (described in table
2) were denoted as follows: asterisks (*) p deletion, insertion and nonsense mutations; diamond () p missense mutation; circles (●) p
GEFS missense mutations reported by Escayg et al. (2000, 2001); and squares () p GEFS missense mutations reported by Wallace et al
(2001).
Table 1
Sequence of the Intronic Primers (5′r3′) Used for the Mutation Analysis of SCN1A
Exon 5′ Primer (Forward) 3′ Primer (Reverse)
No. of Base Pairs
in PCR Product
1 TCATGGCACAGTTCCTGTATC GCAGTAGGCAATTAGCAGCAA 589
2 TGGGGCACTTTAGAAATTGTG TGACAAAGATGCAAAATGAGAG 391
3 GCAGTTTGGGCTTTTCAATG TGAGCATTGTCCTCTTGCTG 314
4 AGGGCTACGTTTCATTTGTATG TGTGCTAAATTGGAATCCAGAG 421
5 CAGCTCTTCGCACTTTCAGA TCAAGCAGAGAAGGATGCTGA 307
6 AGCGTTGCAAACATTCTTGG GGGATATCCAGCCCCTCAAG 477
7 GACAAATACTTGTGCCTTTGAATG ACATAATCTCATACTTTATCAAAAACC 362
8 GAAATGGAGGTGTTGAAAATGC AATCCTTGGCATCACTCTGC 581
9 AGTACAGGGTGCTATGACCAAC TCCTCATACAACCACCTGCTC 440
10 TCTCCAAAAGCCTTCATTAGG TTCTAATTCTCCCCCTCTCTCC 544
11 TCCTCATTCTTTAATCCCAAGG GCCGTTCTGTAGAAACACTGG 670
12 GTCAGAAATATCTGCCATCACC GAATGCACTATTCCCAACTCAC 372
13 TGGGCTCTATGTGTGTGTCTG GGAAGCATGAAGGATGGTTG 543
14 TACTTCGCGTTTCCACAAGG GCTATGCAGAACCCTGATTG 433
15 ATGAGCCTGAGACGGTTAGG ATACATGTGCCATGCTGGTG 544
16 TGCTGTGGTGTTTCCTTCTC TGTATTCATACCTTCCCACACC 658
17 AAAAGGGTTAGCACAGACAATG ATTGGGCAGATATAATCAAAGC 489
18 CACACAGCTGATGAATGTGC TGAAGGGCTACACTTTCTGG 567
19 TCTGCCCTCCTATTCCAATG GCCCTTGTCTTCCAGAAATG 445
20 AAAAATTACATCCTTTACATCAAACTG TTTTGCATGCATAGATTTTCC 395
21 TGAACCTTGCTTTTACATATCC ACCCATCTGGGCTCATAAAC 579
22 TGTCTTGGTCCAAAATCTGTG TTGGTCGTTTATGCTTTATTCG 283
23 CCCTAAAGGCCAATTTCAGG ATTTGGCAGAGAAAACACTCC 378
24 GAGATTTGGGGGTGTTTGTC GGATTGTAATGGGGTGCTTC 600
25 CAAAAATCAGGGCCAATGAC TGATTGCTGGGATGATCTTG 483
26a AGGACTCTGAACCTTACCTTGG TGTACATGTTCACCACAACCAG 589
26b TGTGGGAACCCATCTGTTG CCATGAATCGCTCTTCCATC 418
26c TGCTTTTACAAAGCGGGTTC GTTTGCTGACAAGGGGTCAC 592
RP11-2I8 (Genbank accession number AC010127), the
cDNA sequence of SCN8A (Genbank accession number
XM_006838), and the protein sequence of SCN1A (Es-
cayg et al. 2000). Recently, the complete cDNA and
protein sequence of SCN1A was submitted to Genbank
(accession numbers AF225985 and AAK00217). This
sequence represents an alternatively spliced form of
SCN1A that was described by Schaller et al. (1992). The
protein sequence published by Escayg et al. (2000) con-
tains an additional 11 amino acids at the 3′ end of exon
11, which encode part of the cytoplasmatic loop between
DI and DII.
Mutation Detection and Molecular-Genetic Analysis
Intronic primer pairs were designed for each of the
26 exons, on the basis of the genomic sequence, using
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Table 2
SCN1A Mutations in Patients with SMEI
Patient
Number
Location
in SCN1A
DNA
Changea
Position in
SCN1A Mutation Protein Change
EP 153 Exon 5 c.657-658delAG DI S4 Frameshift, premature stop codon S219fsX275
EP 78 Exon 5 c.664CrT DI S4 Premature stop codon R222X
EP 147 Exon 16 c.2956CrT DII S6 Missense mutation L986F
EP 91 Exon 16 c.3299-3300insAA DII-DIII linker Frameshift, premature stop codon K1100fsX1107
EP 64 Intron 22 IVS221GrA DIII S5-S6 pore Splice donor 
EP 90 Exon 26 c.5010-5013delGTTT DIV S4-S5 loop Frameshift, premature stop codon L1670fsX1678
EP 89 Exon 26 c.5536-5539delAAAC C-terminal Frameshift, premature stop codon S1846fsX1856
a Numbering of mutations started from the initiating ATG codon, as described by Escayg et al. (2000).
the Primer3 program (table 1). Exons and splice-site
junctions were amplified using PCR, from 10 ng genomic
DNA in a standard PCR procedure that used Platinum
Taq (Life Technologies). Next, PCR fragments were de-
natured at 95C for 4 min, were slowly cooled to room
temperature, and subsequently were analyzed by dena-
turing high performance liquid chromatography
(DHPLC) on the WAVE automated instrument (Trans-
genomic), as described elsewhere (Underhill et al. 1997).
Each fragment with an aberrant DHPLC pattern was
purified using the PCR product presequencing kit (USB).
Subsequently, the products were sequenced using the
BigDye Terminator Cycle Sequencing kit (PE Applied
Biosystems) and forward and reverse primers. Sequence
reactions were performed on an ABI 3700 automated
sequencer (PE Applied Biosystems). Data were collected
and analyzed using the ABI DNA sequence analysis soft-
ware, version 3.6.
We used pyrosequencing, as described by Alderborn
et al. (2000), or PCR-RFLP analysis to screen the control
population for the presence of the SCN1A mutations
observed in the patients. The following primers were
used for pyrosequencing: 5′-AAATCGTCTTCAATGC-
TCGG-3′ (c.657-658delAG), 5′-GAAATCGTCTTCA-
ATG-3′ (c.664CrT), 5′-AGAAGCAAGGCCAGAAAG-
3′ (c.2956CrT), 5′-GTTGAAAAATACATTATTG-3′
(c.3299-3300insAA), 5′-TGTATGCAGCAGTTGAT-
TCC-3′ (IVS221GrA), and 5′-CAATCTGCCACAAC-
CAAA-3′ (c.5536-5539delAAAC). The restriction en-
zymeHincII was used for the PCR-RFLP, thereby cutting
the wild-type 589-bp fragment of exon 26a into frag-
ments of 483 and 106 bp. The c.5010-5013delGTTT
mutation creates an extra HincII restriction site in exon
26a, and digestion of the fragment results in three frag-
ments, of 254, 225, and 106 bp.
The SCN1A mutations were described according to
the nomenclature established by den Dunnen and An-
tonarakis (2000), and numbering was started from the
initiating ATG codon, as described by Escayg et al.
(2000).
Paternity Testing
We genotyped D21S188, a multiallelic microsatellite
marker on chromosome 21p (Wang et al. 1999). This
marker shows an average of 16 distinct alleles derived
from eight chromosomes. In addition, we genotyped sev-
eral highly informative microsatellite markers on chro-
mosomes 17 (D17S785, D17S802, and D17S1847) and
18 (D18S51, D18S68, and D18S465). Heterozygosity
frequencies of the chromosome 17 and 18 markers are
74%–89% (CEPH genotype database).
Results
SCN1A Mutation Analysis
All 26 exons and exon-intron boundaries of SCN1A
were analyzed for mutations in seven patients with SMEI
by DHPLC analysis of PCR-amplified fragments (table
1). In each patient with SMEI, we observed a single
aberrant SCN1A fragment (table 2). Subsequent sequence
analysis identified a heterozygous mutation in each pa-
tient: three out-of-frame deletions; one insertion; and one
nonsense, one splice-donor, and one missense mutation
(fig. 2). Table 2 summarizes the mutation data, and fig-
ure 1 illustrates the location of the mutations within the
SCN1A protein. The deletions and insertion result in a
frameshift with a premature stop codon: c.657-
658delAG, c.3299-3300insAA, c.5010-5013delGTTT,
and c.5536-5539delAAAC. The 5′ splice-site mutation
(IVS221GrA)most likely leads to either exon skipping
or use of a cryptic splice-donor site. A potential splice-
donor consensus GT starts at IVS2245, which, if used,
results in a premature stop codon in exon 23. The mis-
sense mutation c.2956CrT results in a change from leu-
cine to phenylalanine amino acid. The leucine at codon
986 is highly conserved among paralogical and orthol-
ogical sodium-channel a-subunits (fig. 3). Most likely
the L986F causes severe damage to SCN1A.
We used sequencing analysis to determinewhether any
patient’s mutation was present in either of the unaffected
parents. In all cases, the mutation was absent from the
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Figure 2 Chromatograms of the SCN1A mutations in compar-
ison with SCN1A wild-type sequences. Exonic sequences are in upper-
case; intronic sequences are in lowercase.
Figure 3 Evolutionary conservation of SCN1A. Sequence align-
ment and evolutionary conservation of the 986L residue (boxed).
parents. Also, for all patients, paternity was confirmed
using several microsatellite markers. For each mutation
(except for the c.5010-5013delGTTT mutation), we de-
veloped a pyrosequencing assay and showed that the
mutations were absent from 92 control individuals. The
c.5010-5013delGTTT mutation creates a newHincII re-
striction site, and we used PCR-RFLP to show that the
mutation was absent in 92 control individuals (data not
shown).
Phenotype of Patients with SMEI
Among the seven patients with SMEI, the age at onset
of disease was 2–6 mo (table 3). In all patients, the
earliest seizures were generalized; in four of the seven
patients, these seizures were associated with fever. Sub-
sequent seizures included secondary generalized tonic-
clonic, myoclonic, absence, and simple and complex par-
tial seizures. In all patients, the seizures were resistant
to therapy. All patients became mentally retarded, and
five patients have ataxia. One patient died at the age of
4 years.
Discussion
In seven patients with SMEI, we identified a heterozy-
gous mutation in SCN1A that was absent in their par-
ents, thereby providing substantial evidence that (1)
SMEI has a genetic etiology and (2) de novo mutations
in SCN1A are probably a major cause of SMEI. Het-
erozygous SCN1A mutations have also been reported in
families with autosomal dominant GEFS. However, all
GEFS mutations are missense mutations that display
reduced penetrance. In contrast, all cases of SMEI
occur in isolated patients. The difference in phenotype
and severity is reflected in the nature of SCN1A mu-
tations identified in patients with SMEI. In five of
seven patients with SMEI, we identified frameshift
deletions (c.657-658delAG, c.5010-5013delGTTT,
c.5536-5539delAAAC) or an insertion (c.3299-
3300insAA) or a nonsense mutation (c.664CrT). Also,
in one patient with SMEI, we identified a GrA transition
in the conserved GT consensus sequence of the splice-
donor site of intron 22. The consequence of this mu-
tation can only be elucidated by analyzing the mutated
transcript or protein. In one patient with SMEI, we iden-
tified a missense mutation at codon 986 (L986F), which
is located within domain DII S6 of the SCN1A protein.
Since codon 986 is highly conserved among a-subunits
of human and other species, it can be predicted that this
mutation may have a deleterious effect on SCN1A.
Thus, in the majority of patients with SMEI, the mu-
tation results in early termination of translation, thereby
producing a C-truncated SCN1A protein from one of
the SCN1A alleles. Rapid degradation of these trun-
cated transcripts or proteins could lead to a loss of func-
tion comparable with haploinsufficiency. Alternatively,
some of the transcripts could lead to abnormal proteins
Claes et al.: SCN1A and Myoclonic Epilepsy of Infancy 1331
Table 3
Clinical Features of Seven Patients with SMEI with Mutations in SCN1A
PATIENT
CHARACTERISTIC
DATA FOR PATIENTS
EP 64 EP 78 EP 89 EP 90 EP 91 EP 147 EP153
Sex Male Male Male Female Female Female Male
Year of birth 1994 1994 1988 1995 1992 1998 1990
Race White White White White White White White
Status at birth Normal Normal Normal Normal Normal Normal Normal
Family history:
Consanguinity       
Febrile seizures  Paternal uncle  Mother   Maternal niece
Epilepsy     Maternal niece,
paternal uncle  
First seizure:
Age 5 mo 6 mo 2 mo 4 mo 4 mo 4 mo 3 mo
Type GTCS GCS GTS GTCS GCS GTCS GTCS
Fever-associated       
Other seizures:
Secondary GTCS       
Myoclonic seizures:       
Age at onset 17 mo 110 mo 13 mo 112 mo 18 mo 112 mo 13 years
Frequency Daily Daily Daily Rarely Daily Rarely Rarely
Other seizures CPS Abs  Abs  Abs, SPS Abs
Other features:
Therapy-resistant       
Mental retardation Moderate Moderate Severe Severe Severe Moderate Moderate
Ataxia       
Age at last
examination 6 years 6 years 10 years 5 years 6 years 2 years 4 yearsa
NOTE.—p absent;  p present;  p probably present; GTCSp generalized tonic-clonic seizures; GCS p generalized clonic seizures;
GTS p generalized tonic seizures; Abs p absence seizures; SPS p simple partial seizures; CPS p complex partial seizures.
a Died at age 4 years.
with a toxic increase in function. In this respect, it
is of intrest that heterozygous knockout mice for three
voltage-gated sodium-channel a-subunits (SCN2A/,
SCN8A/, and SCN10A/) do not display an abnor-
mal phenotype and appear to develop normally. In con-
trast, homozygous knockout mice for these genes have
a severe phenotype. SCN2A/ mice die, as a result of
severe hypoxia and extensive neuronal cell death, within
1–2 d of birth (Planells-Cases et al. 2000). SCN8A/
mice display a paralytic phenotype, withmuscle atrophy
and ataxia, and die 4 wk after birth (Burgess et al.
1995). SCN10A is a sensory-neuron–specific voltage-
gated sodium channel. SCN10A/ mice have partial
deficits in perception of noxious thermal, mechanical,
and inflammatory stimuli (Akopian et al. 1999). Given
these observations, we conclude that the analysis of mu-
tant transcripts and proteins is necessary for elucidation
of the exact pathogenetic mechanism of heterozygous
SCN1A mutations in patients with SMEI.
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